 

**Title:** EXPERIMENTAL EVALUATION OF THE EFFECT OF PYCNOGENOL AND ITs FRACTIONS ON ENDOTHELIAL DYSFUNCTION IN DIABETIC RATS

**Scientific Track:** Pharmacological Advances

**Full Name**: Naguibou M. DJIBRIL

**Affiliation:** Unité de Pharmacologie, Département des Sciences fondamentales et biologiques,

Faculté des Sciences de la Santé (FSS) 01 BP 188 ; Université d’Abomey Calavi (UAC) Cotonou (Rép. Du Bénin).

**Abstract text:** The present study evaluates antihyperglycaemic activity of fractionated Pycnogenol and its ability to improve endothelial dysfunction in diabetic animals. The aim of this study was to isolate from Pycnogenol mixture its active compounds and compare their efficacy on observed parameters. Pycnogenol mixture was fractioned by re-extracting with petroleum ether, chloroform, ethyl acetate and butanol, subsequently. Pycnogenol mixture and fractions (butanolic, water, ethyl acetate) were administered from 6 weeks to diabetic rats. Blood glucose levels were assessed from the arterio-venous blood at the beginning of the experiment and at the end of the experiment. Endothelial dysfunction was evaluated as the contractile responses to phenylephrine and acetylcholine. The amount of collagen I and III was assessed from thoracic aorta after picrosirius red staining. For the confirmation of the changes on molecular level, we determined the endothelial NO-synthase and heat shock protein 90 expression from left ventricle.

Overall, the result suggest that fractions are not so effective on observed parameters as Pycnogenol mixture itself, indicating synergistic effect of the plant constituents.

**Short Biography:**

Graduated from the Pharmaceutical Faculty (FaF-UK) -***Comenius University*** in ***Bratislava (Slovak-Rep. Ex-Czechoslovakia)*** as PharmD. Clinical Pharmacist –Jun 1994; I continued my Post graduate study in the ***Medical Faculty*** of the same University in the Institute of Pharmacology & Clinical pharmacology where I got my PhD in Pharmacology (26th of June 1998)

I’m teaching Pharmacology ***& Toxicology*** and other ***Pharmaceutical science’s subjects as Pharmacokinetics*** (Both in French and English) at the Medical and Pharmaceutical faculty of University of Abomey Calavi (UAC) in Cotonou (Gouvernement University). Despite of my teaching experiences, I occupied different high positions at the Ministry of Health of Benin Rep. (General Secretary & Deputy head of cabinet of the Minister of Health) and in Academics: Dean (for 05years) of Medical & pharmaceutical faculty (HNAUB) ; Vice Chancellor of RIUB/ UOA –Georgia (USA)

-------------------------------------------

“Dr. Scientist is currently working as Lecturer & researcher at the ***University of Abomey Calavi*** (**UAC**).

-Dr Scientist received his Doctoral degree or PhD on June 28th 1998 from ***Comenius University*** Bratislava-SLOVAKIA.

-Dr Scientist completed his Masters June 1994 from the same University. He then worked at the Institute of Pharmacology & Clinical Pharmacology, served as Associate Professor and Professor at the University in **BENIN -Republic**.

-Dr. Scientist has authored several publications in various journals and books. His publications reflect his research interests in *Pharmacological advances*.

-Dr. Scientist is also an Associate Editor of the Journal ***IJBR&R***. (International Journal of Biochemistry Research & Review)

-Dr. Scientist is serving as a member or fellow in Association of WASOP *(West African Society of Pharmacology*). He is currently in charge of ongoing scholarly project.

-Dr. Scientist is awarded or honored by ***IJBRR***.

**Research Interest:**

Since Pycnogenol exhibited adjuvant effect in combined therapy in several studies in different diagnosis [13; 14; 15], we focused in this study on fractionating his mixture, because there are just a few studies in which Pycnogenol fractions were used. We were interested whether Pycnogenol fractions are more effective than whole mixture or not. We evaluated antihyperglycaemic activity and the impact of administration of Pycnogenol fractions on endothelial dysfunction, changes of collagen level and expression of proteins in diabetic animals.

**Keywords:** *diabetes – Pycnogenol mixture – fractions – oxidative stress – endothelial dysfonction-eNOS- Hsp90 - Collagen*

**References:**

[1] Jay D, Hitomi H, Griendling KK.

Oxidative stress and diabetic cardiovascular complications.

Free Radical Biol Med. 2006; 40:183-192.

[2] Ryan EA, Pick ME, Marceau C.

Use of alternative medicines in diabetes mellitus.

Diabetic Med 2001;18 (3):242–245.

[3] Choudhary SK et al.

Comprehensive evaluation of anti-hyperglycemic activity of fractionated

Momordica charantia seed extract in alloxan-induced diabetic rats.

Evid Based Complement Alternat Med 2012; doi:10.1155/2012/293650.

[4] Cesarone MR, et al.

Improvement of diabetic microangiopathy with pycnogenol: a prospective, controlled study.

Angiology 2006; 57(4):431-436.

[5] Kolacek M, et al.

Effect of natural polyphenols, pycnogenol® on superoxide dismutase and nitric oxide synthase in diabetic rats.

Prague Med Rep 2010;111 (4):279-288

[6] Parveen K, et al.

Protective effects of Pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats.

Chem Biol Interact 2010; 186 (2):219-227.

[7] Virgili F, Kim D, Packer L.

Procyanidins extracted from pine bark protect α-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett 1998; 431(3):315-318.

[8] Rosei EA, Rizzoni D.

Small artery remodeling in diabetes.

J Cell Mol Med 2010;14(5):1030-1036.

[9] Wang Y, Marsden PA.

Nitric oxide synthases: gene structure and regulation.

Adv Pharmacol 1995; 34:71–90.

[10] Chatterjeea A, Catravas JD.

Endothelial nitric oxide (NO) and its pathophysiologic regulation.

Vasc. Pharmacol 2008; 49(4-6):134-140.

[11] Lin KY, et al.

Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.

Circulation 2002;106:987

[12] Hlavačková L, et al.

The effect of indapamide on development of myocardial hypertrophy and fibrosis in L-NAME-induced hypertension in rat.

Physiol Res 2011;60: 845-852.

[13] Stuard S, et al. Kidney function in metabolic syndrome may be improved with Pycnogenol®.

Panminerva Med 2010;52 (2 Suppl 1):27-32.

[14] Belcaro G, et al.

Investigation of Pycnogenol® in combination with coenzymeQ10 in heart failure patients (NYHA II/III).

Panminerva Med 2010; 52(2 Suppl 1):21–25.

[15] Zibadi S, et al.

Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation.

Nutr Res. 2008; 28(5): 315-320

[16] Jankyova S, et al. Glucose and blood pressure lowering effects of Pycnogenol® are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy. Pathol Res Pract 2012; 208 (8):452– 457.

[17] Krenek P, et al.

Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy.

Can J Physiol Pharmacol 2006;84(12):1245-1250.

[18] Jankyova S, et al. Pycnogenol efficiency on glycaemia, motor nerve conduction velocity and markers of oxidative stress in mild type diabetes in rats.

Phytother Res 2009; 23 (8):1169–1174.

[19] Klimas J. et al. Pycnogenol improves left ventricular function in streptozotocin-induced diabetic cardiomyopathy in rats. Phytother Res 2010;24(7):969-974.

[20] Cheynier V, et al. Size separation of condensed tannins by normal phase high performance liquid chromatography.

Methods Enzymol. 1998;299 :178–184.

[21] Liu X, Zhou HJ, Rohdewald P.

French maritime pine bark extract pycnogenol dose-dependently lowers glucose in type 2 diabetic patients.

Diabetes Care 2004; 27:893-896.

*This research was supported by Grant, BENIN*.

**Contact Details**:

**Email Id**: nadjim9497@yahoo.fr

**Mobile No**: (+229) 96583346

**Office No**: (+229) 21043398